Glaukos Corporation (GKOS)
NYSE · Healthcare · Medical Devices
$164.01+0.16%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.7B
- Forward P/E
- 313.3
- 52-week range
- $73.16 – $191.62
- 52-week change
- +89.04%
- EPS (trailing)
- −$3.26
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $507M (+32.33%)
- Net income
- −$188M
- Operating margin
- −39.3%
- Diluted EPS
- −$3.28
- Free cash flow
- −$22.4M
From the company’s annual report on SEC EDGAR.
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Headquarters: Aliso Viejo, United States · 1,094 employees · glaukos.com